CervoMed (CRVO) vs Dogwood Therapeutics (DWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CervoMed (CRVO) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 63.1% versus a loss of 75.0%. Over five years, CRVO leads with a -90.9% price change compared with -98.8% for DWTX. CervoMed is the larger company by market cap ($48.7 million vs $47.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | DWTX |
|---|---|---|
| Share price | $3.22 | $1.40 |
| Market cap | $48.68M | $47.59M |
| 1-day change | -1.83% | -0.71% |
| YTD return | -58.48% | -66.35% |
| 1-year return | -63.15% | -75.00% |
| 5-year return | -90.89% | -98.80% |
| P/E ratio (TTM) | — | 0.64 |
| EPS (TTM) | $-3.21 | $2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $7.04 |
| 52-week low | $2.13 | $1.28 |
| Distance from 52-week high | -67.80% | -80.12% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +378.26% | +900.00% |
| Average volume | 339.08K | 63.50K |
| Shares outstanding | 15.12M | 33.99M |
| Employees | 15 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVO has outperformed DWTX by 11.9 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
CRVO vs DWTX FAQ
Which is bigger, CervoMed or Dogwood Therapeutics?
CervoMed (CRVO) is larger, with a market capitalization of $48.68M compared with $47.59M for Dogwood Therapeutics (DWTX).
Which stock has performed better over the past year, CRVO or DWTX?
CRVO returned -63.15% over the past 12 months, compared with -75.00% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Dogwood Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.